

Neuroscientific Biopharmaceuticals

Name Change to Miro Sciences

Miro Sciences Ltd (ASX: MSX) formerly NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) advises that, following shareholder approval at the Annual General Meeting held on 15 October 2026, the Company's change of name to Miro Sciences Ltd has been formally registered with the Australian Securities and Investment Commission (ASIC).

The change of name reflects the Company's evolution into a clinical-stage biotechnology company focused on advancing its proprietary StemSmart™ cell therapy platform and the development of potential treatments for patients with refractory Crohn's disease.

The new corporate identity aligns with the Company's next phase of development as it progresses preparations for its planned phase 2 clinical trial in Australia and the United States.

Change of ASX Code

In conjunction with the name change, the Company's ASX ticker code will change from NSB to MSX, effective from the commencement of trading, today, Wednesday 28 October 2026.

The Company's new name and ASX ticker will be reflected across its corporate communications, investor materials and website.

The change of name will not affect the Company's existing operations, strategy or shareholders' rights. No action is required by shareholders.

This announcement is authorised by the Board of **Miro Sciences Ltd**.

- ENDS -

For Further Information, please contact:

Nathan Smith
Chief Executive Officer
Miro Sciences Ltd
ir@mirosciences.com

Jane Morgan
Investor and Media Relations
Jane Morgan Management
jm@janemorganmanagement.com.au

